Baxion
Screening
Tags
Alerts
Theme
Fate Therapeutics Inc.
FATE
·
NASDAQ
·
$2.15
Share Price as of 11/2
·
$251M
Market Cap as of 11/2
Categorized
Chronological
Ownership
Credit
Contracts
Plans
Incorporation
Transcripts
Tags
Financials
Filter
10-Q
Q2 ended 06/30/26
08/13/26
10-Q
Q1 ended 03/31/26
05/13/26
10-K
FY 2025
02/26/26
10-Q
Q3 ended 09/30/25
11/13/25
10-Q
Q2 ended 06/30/25
08/12/25
Disclosures
Filter
8-K
Current report
09/28/26
8-K
Current report
08/13/26
8-K
Current report
06/15/26
8-K
Current report
06/04/26
8-K
Current report
05/13/26
Prospectuses and Registrations
Filter
S-8
Registration of securities for employees
08/13/26
S-8
Registration of securities for employees
10/20/25
S-8
Registration of securities for employees
06/04/25
S-8
Registration of securities for employees
06/10/24
424B3
Prospectus
05/02/24
Proxies
Filter
DEF 14A
Definitive proxy
04/24/26
DEFA14A
Additional proxy materials
04/24/26
DEF 14A
Definitive proxy
04/17/25
DEFA14A
Additional proxy materials
04/17/25
PRE 14A
Preliminary proxy
04/07/25
Ownership
Filter
Form 4
Insider transaction
08/05/26
Form 4
Insider transaction
08/05/26
144
Proposed sale of securities
08/04/26
144
Proposed sale of securities
08/04/26
SC 13G/A
Beneficial ownership (amended)
07/08/26
Other
Filter
ARS
Annual report to shareholders
04/24/26
ARS
Annual report to shareholders
04/17/25
EFFECT
Request for effectiveness
04/29/24
ARS
Annual report to shareholders
04/26/24
CORRESP
Correspondence with the SEC
04/25/24
Latest Filings
Filter
8-K
Current report
09/28/26
10-Q
Q2 ended 06/30/26
08/13/26
8-K
Current report
08/13/26
S-8
Registration of securities for employees
08/13/26
8-K
Current report
06/15/26
Ownership
Filter
Form 4
Insider transaction
08/05/26
Form 4
Insider transaction
08/05/26
144
Proposed sale of securities
08/04/26
144
Proposed sale of securities
08/04/26
SC 13G/A
Beneficial ownership (amended)
07/08/26